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Abstract
Background: Rhodococcus equi is a gram positive, intracellular pathogen of foals worldwide.
The aim of this study was to determine whether there was an increasing resistance occurring in Rhodococcus equi
towards the antibiotics rifampin and erythromycin over a seven year period. The investigation was carried out with
the use of E test strips (epsilometers) for rifampin and erythromycin in order to determine the Minimum Inhibitory
Concentrations (MIC) values of Rhodococcus equi to these antibiotics.
Results: The main results of this study found that the mean MICs were higher for erythromycin than for rifampin
for every year analysed apart from 2008. The results highlight that 75 % (6/8) of the mean MICs for erythromycin
were above the threshold of susceptibility of 0.5 μg/ml and one of the yearly mean MICs for rifampin (2008) was
above the level of ≤ 1 μg/ml. Two soil samples analysed had high MIC values of 2 μg/ml and 3 μg/ml for rifampin
and erythromycin respectively. These samples can be said to have acquired resistance as they are above 1 μg/ml.
Conclusions: The significance of these findings is that R. equi is already a problematic pathogen to treat and if the
bacteria keeps gaining resistance to these antibiotics at rate that has been shown over the last decade, then a new
form of treatment will have to be introduced. Further research into the genomics of Rhodococcus equi will, in time,
shed more light on possible alternatives such as vaccines or new, more effective antimicrobials.
Background
Rhodococcus equi is a gram positive, intracellular soil
saprophytic coccobacillus, classified in the order Actino-
mycetales [1]. First recognised as a pathogen of livestock
by Magnusson in 1923, the bacteria was assigned the
name Corynebacterium equi. It was only in 1977 that it
was reclassified as Rhodococcus equi, (Rhodococcus
means red-pigmented coccus) [2]. Rhodococcus equi is a
worldwide pulmonary pathogen of foals from one to six
months of age.
R. equi is an increasing pathogen of concern and is
one of the leading causes of bronchopneumonia in foals.
The prevalence and virulent nature of the disease has a
major economic impact on the equine industry world-
wide [3, 4]. The simple growth requirements of R. equi
are met by herbivore manure and soil which make farms
and stables an ideal breeding ground for the bacteria.
The nature of this bacterium as a soil –dwelling organ-
ism coupled with intensification of equine breeding
practices and management, makes this disease hard to
control and prevent. Rhodococcus equi can be present in
the environment of virtually all farms. However, some
farms suffer from endemic clinical disease compared to
sporadic and unrecognised clinical cases on others [4].
Foals, in particular, are most at risk of the disease due to
a number of factors, including an undeveloped immune
system and the drop in maternal antibodies [5].
There are a wide range of antimicrobials to which
Rhodococcus equi is susceptible to in vitro.However, find-
ing an antimicrobial that works in vivo is a challenge.
The recommended antibiotic dosage for R. equi infec-
tion has been described as being : 25 mg/kg of erythro-
mycin orally every 8 or 12 h and for rifampin: 5 mg/kg
orally every 12 h, or 10 mg/kg every 24 h for a duration
of 4–9 weeks [6].
Although well tolerated in most foals, the combination
therapy of erythromycin and rifampin can cause adverse
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reactions. The most common side effect is diarrhoea
which is usually self-limiting. However, if the diarrhoea
persists, it can lead to dehydration [7]. One of the most
serious adverse reactions of these antimicrobials is se-
vere hyperthermia and tachypnea, which can often result
in death of the affected foal. These particular side effects
are a significant cause of concern, especially for veteri-
narians in warmer climates[6].
The recent sequencing of the R. equi genome has re-
vealed many genes that are resistant to antimicrobials,
the concern would be that these genes, through the use
of prophylactic or improper use of antimicrobials, could
manifest over the coming years [6]. The nature of R.
equi as a soil saprophyte means that it possesses many
chromosomal resistance determinants that have evolved
with the core genome. These determinants play a role in
counteracting the action of naturally occurring antimi-
crobials. [8]. Resistance to rifampin has been shown to
occur through a mutation in the ß subunit of rpoB gene
[9]. The resistance mechanisms of macrolide resistance
have not yet been determined on a molecular level.
However, R. equi isolates that are resistant to either
erythromycin, azithromycin or clarithromycin, are usu-
ally resistant to all three [8].
This study sought to determine whether there is a
trend of resistance occurring for Rhodococcus equi to
erythromycin and rifampin. This was carried out over a
sample range dating from 2007 to 2014 to see if there
was an increase in resistance.
Methods
A total of 74 isolates, positively identified as Rhodococcus
equi that were isolated from clinical samples submitted to
the Irish Equine Centre between the years 2007–2014,
were stored at −80 °C. The isolates were re-cultured using
a pure colony for the inoculation of a fresh agar plate the
MIC values were analysed. The MIC values of these iso-
lates were analysed for both erythromycin and rifampin
using gradient MIC strips (Liofilchem® MIC Test Strips).
The test strips had an easily readable gradient of which
the range was 0.016-256 μg/ml for both antibiotics. The
strips created a clear zone of inhibition that was visible to
the eye and the MIC was determined by establishing
where the zone of inhibition began.
Results
The results of the isolates analysed were grouped ac-
cording to the year in which they were isolated. The
MIC value was determined for each of the 74 isolates for
both antibiotics. The range on each antibiotic strip was
0.016-256 μg/ml. The mean MIC values for each year
can be observed in Table 1.
The table shows that the mean MIC values vary sig-
nificantly from year to year. However, they are still quite
high. Rhodococcus equi is thought to be susceptible to ri-
fampin at ≤ 1 μg/ml, and to erythromycin at ≤ 0.5 μg/ml.
Therefore, according to these results, 75 % (6/8) of the
mean MICs for erythromycin were above the threshold
of susceptibility and one of the yearly mean MICs for ri-
fampin (2008) was above the level of ≤ 1 μg/ml. The
mean MIC concentrations for erythromycin were higher
in nearly every year (exception 2008) compared to that
of rifampin. Two isolates of Rhodococcus equi from the
year 2009 were isolated from soil samples. The isolates
had the highest MIC levels of all the 74 isolates, the
MICs for the soils samples were 2 μg/ml for rifampin
and 3 μg/ml for erythromycin. The samples were isolates
from the Kildare region.
Statistical Analysis (Table 2)
Figure 1 above graphically highlights the MIC values for
each antibiotic throughout the sample period. There are
outliers in 2009, these are soil samples. It can be
hypothesised that these samples taken from the soil may
have virulence plasmids which could be a reason for
their resistance and therefore their high MIC values.
Figure 2 above illustrates that the majority of the sam-
ples (47 %) originated from Co. Kildare and 20 % origin-
ating from Co. Cork. this is to be expected as most of
the thoroughbred horses in Ireland are located in Kildare
as well as the most amount of Equine veterinary hospi-
tals, however further research would be warranted into a
geographical link to resistant strains of the bacteria.
Discussion
The aim of this project was to determine whether there
was a trend of resistance occurring for Rhodococcus equi
to the antimicrobials erythromycin and rifampin.
This analysis was carried out using isolates dating
from 2007 to 2014 in order to establish if there was an
increase in the Minimum Inhibitory Concentrations
(MIC) over this timespan. This study was a follow on
study from Buckley et al.,[10] who assessed the MIC
values for R. equi isolates from pre- 2000 to 2006.
Table 1 Mean and ranges of the MIC concentration of R. equi
to rifampin and erythromycin for each year (μg/ml)
Year of sample
(number of samples)
Rifampin (range) Erythromycin (range)
2014 (4) 0.300 (0.19 - 0.38 ) 0.657 ( 0.38- 1.00 )
2013 (10) 0.345 ( 0.19 - 0.75 ) 0.800 ( 0.75- 1.50 )
2012 (10) 0.308 ( 0.125-0.500 ) 0.439 ( 0.25- 0.75 )
2011 (10) 0.408 ( 0.19- 0.75 ) 0.514 ( 0.38-0.75)
2010 (10) 0.325 (0.125- 0.50 ) 0.775 ( 0.50- 1.00 )
2009 (10) 0.689 ( 0.25- 2.00 ) 1.125 ( 0.50- 3.00 )
2008 (10) 1.025 ( 0.50- 1.50 ) 0.115 ( 0.047-0.19 )
2007 (10) 0.489 ( 0.125 - 1.50 ) 1.225 ( 0.50- 2.00 )
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The 74 samples used in this study were analysed for
their MIC values to erythromycin and rifampin using
gradient strips for each antibiotic.
The MIC levels varied from year to year in this study.
However, for erythromycin 75 % (6/8) of the mean MICs
for all the years were above 0.5 μg/ml which indicates a
trend of clinical resistance. According to Giguere et al.,
[7] the level of susceptibility for R. equi to erythromycin
is ≤ 0.5 μg/ml . In the previous study conducted by Buck-
ley et al., [10], only the mean MIC for the year 2006 was
above this level at 0.583 μg/ml, indicating that the mean
MIC levels may in fact be increasing with time. For ri-
fampin in 2008, the mean MIC was above the suscep-
tible level of 1 μg/ml. In the previous study, no levels for
rifampin were above this level. Rifampin is always used
in combination with another drug due to the fact that re-
sistance to rifampin can occur quite quickly. Two isolates
in this present study originated from soil samples and
these samples had the highest MIC values of 2 μg/ml and
3 μg/ml for rifampin and erythromycin respectively. This
is a worryingly high MIC value and may indicate that viru-
lent R. equi is ubiquitous in the environment of farms.
This indication warrants further research.
Buckley et al., [10] found that the MIC for rifampin in-
creased from 1996 to 2006 and the MIC for erythro-
mycin went from 0.258 μg/ml prior to the year 2000 to
0.583 μg/ml in 2006. The present study found that these
MIC values have further increased in the last decade and
the mean MIC values for 2014 were 0.657 μg/ml for
erythromycin and 0.300 μg/ml for rifampin. This is a sig-
nificant increase in MIC levels especially for a bacteria
that is difficult to treat due to its intracellular nature and
virulence plasmids.
The regions, where the isolates originated from, were
also evaluated and the majority came from Kildare. This
could be due to the fact that the majority of big stud
farms are located in Co. Kildare. However, it could also
point to a geographic link to R. equi virulence.
Data describing antimicrobial susceptibility for equine
Rhodococcus equi isolates is scarce [11]. However, the inci-
dence of resistant R. equi isolates is on the rise in recent
years. A study by Boyen et al., [11] looked at antimicrobial
resistance to R. equi. The study examined MIC values for
R. equi to azithromycin, erythromycin , clarithromycin
and rifampin. The results were similar to this present
study in that of the 15 isolates tested for erythromycin, 10
were above 0.5 μg/ml, 5 were ≤ 1 μg/ml and for rifampin,
one sample had an MIC of ≤ 1 μg/ml and 8 samples
were ≤ 8 μg/ml. This suggests that resistance of R. equi to
rifampin is increasing.
Takai et al., [9] described rifampin resistance back
in 1997 and linked the resistance to the incorrect use
of antibiotic therapy. Macrolide resistance seems to
be more widespread than rifampin resistance. In this
study, the mean MIC values were higher in every year
Fig. 1 MIC Values for Rifampin and Erythromycin from 2007 to 2014 (μg/ml)
Table 2 Descriptive Statistics describing the Rifampin and
Erythromycin MIC values measured yearly from 2007 to 2014
Rifampin MIC Values
2007 2008 2009 2010 2011 2012 2013 2014
Mean 0.49 1.03 0.69 0.33 0.41 0.31 0.35 0.30
Median 0.38 0.88 0.38 0.38 0.38 0.25 0.25 0.32
Variance 0.16 0.19 0.49 0.01 0.03 0.02 0.03 0.01
Std. Deviation 0.40 0.43 0.70 0.12 0.16 0.13 0.17 0.10
Minimum 0.13 0.50 0.25 0.13 0.19 0.13 0.19 0.19
Maximum 1.50 1.50 2.00 0.50 0.75 0.50 0.75 0.38
Range 1.37 1.00 1.75 0.37 0.56 0.37 0.56 0.19
Interqaurtile Range 0.33 0.81 0.63 0.19 0.25 0.18 0.16 0.18
Erythromycin MIC Values
Mean 1.23 0.12 1.13 0.78 0.55 0.44 0.80 0.66
Median 1.25 0.11 0.75 0.75 0.50 0.38 0.75 0.63
Variance 0.20 0.00 1.00 0.03 0.03 0.04 0.08 0.08
Std. Deviation 0.45 0.06 1.00 0.18 0.18 0.19 0.28 0.28
Minimum 0.50 0.05 0.50 0.50 0.38 0.25 0.50 0.38
Maximum 2.00 0.19 3.00 1.00 0.75 0.75 1.50 1.00
Range 1.50 0.14 2.50 0.50 0.37 0.50 1.00 0.62
Interquartile Range 0.56 0.13 1.00 0.31 0.37 0.31 0.13 0.53
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(exception 2008) for erythromycin compared to rifampin.
A study conducted by Burton [12], looked at clinical iso-
lates from a Kentucky breeding farm to investigate macro-
lide and rifampin resistance after a screening program was
initiated to detect subclinical R. equi pneumonia. The
findings showed that seven years after the initiation of the
program, which included prophylactic treatment of foals,
the resistance to macrolides (including erythromycin) and
rifampin, rose significantly. They found that 24 % of pre-
treatment isolates showed resistance compared to a stag-
gering 62 % of post-treatment isolates. This highlights the
emergence of resistance over recent years and the need
for correct diagnosis and treatment only when necessary.
This study highlights the acquired resistance of R. equi
to the combination antibiotics of erythromycin and ri-
fampin. Whilst the MIC values varied from year to year,
this could be due to the relatively small sample size of
10 samples/year. Only four samples were analysed in
2014 due to the timing of the experiment. These were
limitations of the study and further research should in-
clude a larger sample size.
The issue of antimicrobial resistance is a major con-
cern for both human and animal public health. Due to
the emergence of erythromycin and rifampin resistant R.
equi isolates, alternative treatments must be researched
further, as well as better management strategies for the
issue of Rhodococcus equi infection. Better diagnostic
methods should be researched further and avoidance of
prophylactic treatments. Newer generation macrolides
have been suggested as alternatives in combination with
rifampin for the treatment of Rhodococcus equi. Of
these, clarithromycin has been suggested as the best al-
ternative for erythromycin. This was based on a study
where the drug achieved satisfactory concentrations in
the bronchoalveolar cells of foals and pulmonary epithe-
lial lining fluid. This is a beneficial quality for a R. equi
targeting antibiotic due to the intracellular activity of the
bacterium [13]. Further research into the bioavailabity of
antibiotics for the treatment of Rhodococcus equi is
warranted.
Conclusions
The overall conclusion from this study finds that the
MIC values of erythromycin and rifampin to Rhodococ-
cus equi have increased from levels before the year 2000
to 2014. This study highlighted that MIC levels for
erythromycin are continuously higher than that of rifam-
pin. However, the levels of rifampin, whilst not increas-
ing from 2007 to 2014, are much higher than 2000–
2006. The emergence of resistance to Rhodococcus equi
further highlights the need for development of a suitable
vaccine and for alternative ways to treat the disease. En-
vironmental samples have been shown to have high MIC
values to rifampin and erythromycin. This is worrying
due to the nature of exposure to virulent R. equi from
foals in their environment. Further research is needed to
investigate the frequency and rate of acquired resistance
of virulent R. equi isolates to erythromycin and rifampin.
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Fig. 2 Samples analysed grouped by county of origin
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